Could a GLP-1 RA be the Correct Answer for Your Adult Patients With T2D and ASCVD?Industry Webcast Sponsored by Novo Nordisk; Not for CME/CE Credit

Join us to compete with your colleagues in this fun and interactive game as we learn more about the increased risk of ASCVD in patients with T2D, and guideline recommendations on when to use a GLP-1 RA to reduce the risk of MACE. The fun continues with questions about a GLP-1 RA and its clinical trials, including a cardiovascular outcomes trial and glycemic control trials.

Watch

CME/CE Information

0 Credits - Not for CME/CE Credit

Release Date: 12/13/2024

Expiration Date: 12/13/2024

Topics

Faculty

Payal Kohli, MD, FACC

Faculty

Payal Kohli, MD, FACC

Learn More

Industry Sponsor

Novo Nordisk

Fine Print

Computer System Requirements

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.